Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor
2022 · World Allergy Organization Journal · 27 citations
https://doi.org/10.1016/j.waojou.2021.100621
D
Douglas H. Jones
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
124
Papers
2.4K
Citations
28
h-index
55
i10-index
Douglas H. Jones is an academic researcher from Rocky Mountain Multiple Sclerosis Clinic. The author has contributed to research in topics: Advanced Statistical Methods and Models & Statistical Methods and Inference & Food Allergy and Anaphylaxis Research. The author has an h-index of 28, co-authored 106 publications.
ORCID: 0000-0002-7812-9125Papers by this author
worksThe complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks
2024 · Allergy Asthma and Clinical Immunology · 17 citations
https://doi.org/10.1186/s13223-024-00903-w
C1 esterase inhibitor (C1–INH) response as a supportive diagnostic criterion for patients with suspected hereditary angioedema with normal C1–INH
2025 · World Allergy Organization Journal · 0 citations
https://doi.org/10.1016/j.waojou.2025.101125
INDIRECT TREATMENT COMPARISON (ITC) OF RECOMBINANT C1 INHIBITOR AND SEBETRALSTAT FOR HEREDITARY ANGIOEDEMA ON-DEMAND THERAPY
2025 · Annals of Allergy Asthma & Immunology · 0 citations
https://doi.org/10.1016/j.anai.2025.08.099
Patient-reported disease burden and health care utilization of HAE-nl-C1INH: insights from a real-world survey
2026 · Clinical and Experimental Medicine · 0 citations
https://doi.org/10.1007/s10238-025-02010-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat